Contraceptive Drugs and Devices Top Companies-Recent Developments, Business Strategy, Deal Strategy, Patent Strategy, Benchmarking and Management Outlook

Contraceptive Drugs and Devices Market Size Analysis and Top Companies

The global contraceptive drugs and devices market size is estimated to hit around USD 52.73 billion by 2033, increasing from USD 29.64 billion in 2023 with a CAGR of 5.93% from 2023 to 2033. The top companies operating in the contraceptive drugs and devices market are Abbvie, Inc.,  Afaxys, Inc., Agile Therapeutics,  Bayer AG,  China Resources (Holdings) Co., Ltd., Church & Dwight Co., Inc.,  Cupid Limited, Helm AG,  Johnson & Johnson Services, Inc.,  Organon Group of Companies, Pfizer Inc.,  Veru, Inc.,  Viatris Inc., and Others.

Market Report Coverage

Contraceptive Drugs and Devices Key Players

• Abbvie, Inc.
• Afaxys, Inc.
• Agile Therapeutics
• Bayer AG
• China Resources (Holdings) Co., Ltd.
• Church & Dwight Co., Inc.
• Cupid Limited
• Helm AG
• Johnson & Johnson Services, Inc.
• Organon Group of Companies
• Pfizer Inc.
• Veru, Inc.
• Viatris Inc.

Recent Developments

• In July 2023, the first daily oral contraceptive approved for use in the U.S. without a prescription, Opill (norgestrel) tablet for nonprescription use to prevent pregnancy, was approved by the U.S. Food and Drug Administration. Approval of this progestin-only oral contraceptive pill offers an option for consumers to purchase oral contraceptive medicine without a prescription at grocery stores, convenience stores, drug stores, and online.
• In December 2023, in the UK, researchers initiated the first phase of trials for a revolutionary non-hormonal male birth control pill. This pill is a hormone-free innovation named YCT-529, launched by a Nottingham-based drug development company, Quotient Sciences.
• In December 2024, Three Idaho Republican women launched an organization to preserve access to contraceptives. The aim of this launch was to address confusion between contraceptives and abortion.
• In September 2024, a global leader in women’s healthcare, CooperSurgical, announced the launch of a new inserter designed for single-hand placement of Paragard®. The new single-hand inserter improves the placement procedure for healthcare providers and makes Paragard an even more accessible contraceptive choice for both patients and healthcare providers.

We have prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344